Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Dividends

Explore dividend yields, payout ratios, and historical trends to maximize your investment strategies.

ALVO

Alvotech

May 20 • 10:17AM ET

13.47

Dollar change -0.03
Percentage change -0.22	%

Healthcare • Drug Manufacturers - Specialty & Generic • Luxembourg • NASD

Chart Stock Detail • Compare Perf. • Revenue • Dividends • Options Options Chain • Save to Portfolio • Create Alert

Held by: ONEQ STXK FPXE

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-2.07	Insider Own	80.75%	Shs Outstand	266.82M	Perf Week	1.35%
Market Cap	3.59B	Forward P/E	230.57	EPS next Y	0.06	Insider Trans	0.00%	Shs Float	51.35M	Perf Month	1.89%
Income	-551.73M	PEG	-	EPS next Q	-0.08	Inst Own	7.33%	Short Float	0.46%	Perf Quarter	-15.65%
Sales	91.43M	P/S	39.31	EPS this Y	79.26%	Inst Trans	8.84%	Short Ratio	1.00	Perf Half Y	49.17%
Book/sh	-3.49	P/B	-	EPS next Y	111.59%	ROA	-62.04%	Short Interest	0.24M	Perf Year	62.68%
Cash/sh	0.04	P/C	322.05	EPS next 5Y	-	ROE	-	52W Range	6.70 - 18.00	Perf YTD	17.33%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-579.11%	52W High	-25.17%	Beta	-0.06
Dividend TTM	-	Quick Ratio	0.46	Sales past 5Y	3.37%	Gross Margin	-75.93%	52W Low	101.04%	ATR (14)	0.30
Dividend Ex-Date	-	Current Ratio	0.75	EPS Y/Y TTM	-31067.16%	Oper. Margin	-390.24%	RSI (14)	47.40	Volatility	1.06% 1.82%
Employees	1026	Debt/Eq	-	Sales Y/Y TTM	-	Profit Margin	-603.42%	Recom	2.00	Target Price	20.75
Option/Short	No / Yes	LT Debt/Eq	-	EPS Q/Q	19.59%	Payout	-	Rel Volume	0.10	Prev Close	13.50
Sales Surprise	-41.77%	EPS Surprise	-2004.76%	Sales Q/Q	123.78%	Earnings	May 21 AMC	Avg Volume	237.08K	Price	13.47
SMA20	-2.36%	SMA50	-0.63%	SMA200	15.83%	Trades		Volume	4,025	Change	-0.22%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-29-24	Upgrade	Barclays	Equal Weight → Overweight	$10 → $17
Oct-20-23	Upgrade	Citigroup	Sell → Neutral	$5 → $10
Sep-21-23	Initiated	Barclays	Equal Weight	$10
Sep-07-22	Initiated	Morgan Stanley	Equal-Weight	$10
Sep-06-22	Downgrade	Citigroup	Buy → Sell	$12 → $5
Jul-26-22	Initiated	Citigroup	Buy	$12

May-15-24 09:30AM	Alvotech S.A. Annual General Meeting to be held June 7, 2024 (GlobeNewswire)
May-13-24 08:00AM	Alvotech Announces Webcast of First Quarter 2024 Financial Results on May 22, 2024, at 8:00 am EDT (12 noon GMT) (GlobeNewswire)
May-02-24 07:15AM	Alvotech Announces Participation at BofA Securities Healthcare Conference 2024 (GlobeNewswire)
Apr-30-24 04:00AM	U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira (adalimumab) (Business Wire)
Apr-24-24 04:00AM	Alvotech Announces Topline Results from a Confirmatory Clinical Study for AVT05, a Proposed Biosimilar for Simponi (golimumab) (GlobeNewswire)
06:10AM	Loading…
Apr-19-24 06:10AM	Alvotech signs U.S. agreement to expand access for newly approved high-concentration interchangeable biosimilar to Humira (adalimumab) (GlobeNewswire)
Apr-16-24 05:43PM	Alvotech and Teva Announce U.S. FDA Approval of SELARSDI (ustekinumab-aekn), biosimilar to Stelara (ustekinumab) (Business Wire)
Apr-03-24 07:41AM	Alvotech Hosts Audio Call for Investors at 8:15 am EDT on April 3, 2024 (GlobeNewswire)
Mar-22-24 04:15PM	Alvotech Announces Increase in Number of Own Shares (GlobeNewswire)
Mar-20-24 09:52PM	ALVO Stock Earnings: Alvotech Reported Results for Q4 2023 (InvestorPlace)
04:15PM	Alvotech Reports Financial Results for Full Year 2023 and Provides a Business Update (GlobeNewswire)
Mar-05-24 04:01PM	Alvotech Announces Webcast of Full Year 2023 Financial Results on March 21, 2024, at 8:00 am ET (GlobeNewswire)
Feb-29-24 04:05PM	Alvotech Appoints Interim Chief Quality Officer (GlobeNewswire)
Feb-26-24 09:58AM	TEVA Stock Pops 4% as Teva Receives FDA Approval (InvestorPlace) +7.74%
04:25AM	Alvotech Accepts Offer for the Sale of Shares for a value of approximately USD 166 million at a Purchase price of USD 16.41 (ISK 2,250) per Share (GlobeNewswire)
08:15PM	Loading…
Feb-23-24 08:15PM	Alvotech and Teva Announce U.S. Approval of SIMLANDI (adalimumab-ryvk) injection, the first interchangeable high-concentration, citrate-free biosimilar to Humira (Business Wire)
Feb-15-24 06:30AM	Alvotech Announces Expected Global Market Entry Dates for AVT04 Biosimilar to Stelara (ustekinumab) (GlobeNewswire)
Jan-29-24 04:00AM	Alvotech Announces Positive Top-Line Results from a Pharmacokinetic Study for AVT03, a Proposed Biosimilar for Prolia and Xgeva (GlobeNewswire)
Jan-22-24 10:03AM	Alvotech (ALVO) Up on BLA Update for Two Biosimilar Candidates (Zacks)
Jan-19-24 11:30AM	Alvotech Provides Update on Status of Biologics License Applications for AVT02 and AVT04 (GlobeNewswire) +15.29%
Jan-10-24 03:30AM	STADA and Alvotech secure approval for Uzpruvo, Europes first ustekinumab biosimilar to Stelara (GlobeNewswire)
Jan-03-24 03:30AM	Alvotech Clinical Study Results Demonstrate Therapeutic Equivalence between Biosimilar Candidate AVT06 and Reference Product Eylea (aflibercept) (GlobeNewswire)
Dec-29-23 04:05AM	Biodexa Appoints Ann Merchant to the Board of Directors (GlobeNewswire)
Nov-29-23 04:00AM	Alvotech Announces Positive Top-Line Results from a Pharmacokinetic Study for AVT05, a Proposed Biosimilar for Simponi and Simponi Aria (GlobeNewswire)
Nov-28-23 04:15PM	Alvotech Reports Financial Results for First Nine Months of 2023 and Provides Business Update (GlobeNewswire)
04:15PM	Alvotech Reports Financial Results for First Nine Months of 2023 and Provides a Business Update (GlobeNewswire)
Nov-21-23 08:00AM	Alvotech to Report Financial Results for the First Nine Months of 2023 on November 28, 2023, and Host Business Update Conference Call on November 29, 2023, at 8:00 am ET (GlobeNewswire)
Nov-14-23 07:00AM	Alvotech and JAMP Pharma Announce Receipt of Marketing Authorization for Jamteki (AVT04), the First Biosimilar of Stelara (ustekinumab) (GlobeNewswire)
Nov-10-23 09:30AM	STADA and Alvotech receive positive CHMP opinion for Europes first ustekinumab biosimilar to Stelara (GlobeNewswire)
Nov-07-23 08:00AM	Alvotech to Present at the Jefferies 2023 London Healthcare Conference (GlobeNewswire)
04:00AM	Loading…
Oct-12-23 04:00AM	Alvotech Provides Update on Status of U.S. Biologics License Application for AVT04 (GlobeNewswire)
Oct-05-23 01:21PM	Alvotech and Islandsbanki enter into Market Making Agreement for Shares Trading on Nasdaq Iceland (GlobeNewswire)
Oct-03-23 08:29AM	Kashiv BioSciences Enters into Exclusive Licensing Agreement with Alvotech for Development & Commercialization of a Proposed Biosimilar to Xolair (omalizumab) (Business Wire)
05:00AM	Alvotech Enters into Exclusive Licensing Agreement with Kashiv BioSciences for Development and Commercialization of a Proposed Biosimilar to Xolair (omalizumab) (GlobeNewswire)
Sep-25-23 04:00AM	Alvotech Announces Approval in Japan of AVT04 (ustekinumab), a Biosimilar to Stelara® (GlobeNewswire)
Sep-20-23 04:30AM	Alvotech Provides U.S. Regulatory Update on AVT02, a High-Concentration Interchangeable Biosimilar Candidate to Humira® (adalimumab) (GlobeNewswire)
Sep-11-23 05:00AM	Alvotech to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference (GlobeNewswire)
Sep-05-23 09:30AM	Alvotech Announces Changes to the Leadership Team (GlobeNewswire)
Aug-30-23 04:15PM	Alvotech Reports Financial Results for First Six Months of 2023 and Provides Business Update (GlobeNewswire)
Aug-29-23 05:00AM	Alvotech and Bioventure Announce Approval of AVT02 (adalimumab) in Egypt (GlobeNewswire)
Aug-22-23 09:15AM	Alvotech to Report Financial Results for the First Half of 2023 on August 30, 2023, and Host Business Update Conference Call on August 31, 2023, at 8:00 am ET (GlobeNewswire)
Jul-31-23 04:00AM	Alvotech Completes $100 Million Convertible Bond Private Placement (GlobeNewswire)
Jul-26-23 01:30PM	Northland Capital Markets Institutional Investor Conference (ACCESSWIRE)
Jul-24-23 04:00AM	Teva Pharmaceuticals and Alvotech Provide Update on Strategic Biosimilars Partnership (GlobeNewswire)
Jul-06-23 07:26AM	Should You Exit Alvotech (ALVO)? (Insider Monkey)
Jun-28-23 07:00PM	Alvotech Provides Regulatory Update on Second Biologics License Application for AVT02 (GlobeNewswire)
Jun-12-23 07:00AM	Alvotech and Teva Secure U.S. License Date for AVT04, a Proposed Biosimilar to Stelara® (Business Wire) -9.51%
May-31-23 05:20AM	Alvotech to Participate in Jefferies Healthcare Conference (GlobeNewswire)
May-24-23 05:00AM	Alvotech and Advanz Pharma extend strategic partnership to commercialize five proposed biosimilars in Europe (GlobeNewswire)
May-19-23 05:00AM	Alvotech Reports Financial Results for First three Months of 2023 and Provides Business Update (GlobeNewswire)
May-17-23 05:00AM	Alvotech to Participate in Morgan Stanley Annual Sustainable Finance Summit (GlobeNewswire) -7.35%
May-15-23 05:00AM	Alvotech Issues Annual Equality Report Covering 2022 (GlobeNewswire)
May-10-23 05:00AM	Alvotech enters into commercialization agreement with Polifarma for proposed biosimilar to Eylea® (aflibercept) (GlobeNewswire)
May-05-23 09:00AM	Alvotech S.A. Annual General Meeting to be held June 6, 2023 (GlobeNewswire)
May-04-23 05:00AM	Alvotech Initiates Confirmatory Patient Study for AVT05, a Proposed Biosimilar for Simponi® and Simponi Aria® (GlobeNewswire)
May-03-23 09:00AM	Alvotech to Report First Quarter 2023 Financial Results and Recent Business Highlights on May 18, 2023 and Host Conference Call on May 19, 2023 at 8:00 am ET (GlobeNewswire)
Apr-19-23 05:30PM	Sarah Tanksley Joins Board of Directors for Alvotech hf. and Sandra Casaca Appointed Chief Quality Officer (GlobeNewswire)
Apr-13-23 08:45PM	Alvotech Provides Regulatory Update on AVT02 Biologics License Application (GlobeNewswire)
Mar-28-23 05:00AM	Alvotech Provides Update on Corporate Sustainability Framework (GlobeNewswire)
Mar-17-23 09:10AM	Alvotech to Present Clinical Study Data for AVT04, a Proposed Biosimilar to Stelara®, at 2023 American Academy of Dermatology (AAD) Annual Meeting (GlobeNewswire)
Mar-01-23 04:30PM	Alvotech Reports Financial Results for Full Year 2022 and Provides Business Update (GlobeNewswire)
Feb-27-23 07:15PM	Alvotech Announces Webcast of 2022 Full Year Financial Results at 8:00 am ET on March 2, 2023 (GlobeNewswire)
Feb-14-23 04:01PM	Updated market making agreement with Landsbankinn for Alvotech shares trading on the Nasdaq Iceland market (GlobeNewswire)
Feb-10-23 04:01PM	Settlement of Alvotech Private Share Placement Completed (GlobeNewswire)
Feb-09-23 02:30AM	EMA Confirms Acceptance of Application for AVT04, a Proposed Biosimilar to Stelara® (ustekinumab) (GlobeNewswire)
Feb-06-23 04:00AM	Alvotech enters into commercialization agreement with Advanz Pharma for proposed biosimilar to Xolair® (omalizumab) (GlobeNewswire)
Jan-24-23 04:00AM	Alvotech and Bioventure Announce Approval of AVT02 (adalimumab) as Simlandi in Saudi Arabia (GlobeNewswire)
Jan-23-23 03:25AM	Alvotech Completes $137 Million Private Share Placement (GlobeNewswire)
Jan-13-23 04:00AM	Alvotech and Fuji Pharma Expand Partnership Adding a New Biosimilar Candidate (GlobeNewswire) +5.00%
Jan-11-23 04:00AM	Alvotech Initiates Pharmacokinetic Study for AVT05, a Proposed Biosimilar for Simponi® and Simponi Aria® (GlobeNewswire)
Jan-06-23 07:00AM	Alvotech and Teva Announce Acceptance of U.S. Biologics License Application for AVT04, a Proposed Biosimilar to Stelara® (ustekinumab) (Business Wire) +6.77%
Dec-22-22 04:00AM	Update on U.S. Regulatory Status of AVT02, Alvotechs Proposed High-Concentration, Interchangeable Biosimilar to Humira® (GlobeNewswire) +17.35%
Dec-16-22 06:45AM	Correction to Total Amount in Announcement About Private Placement Published 2022-12-16 09:00 GMT (GlobeNewswire)
06:45AM	Correction to Total Amount in Announcement About Private Placement Published 2022-12-16 09:00 GMT to headline field (GlobeNewswire)
04:00AM	Alvotech Completes $59.7 Million Private Placement (GlobeNewswire)
Dec-08-22 03:30AM	Alvotech Shares Start Trading on Nasdaq Iceland Main Market (GlobeNewswire) +6.95%
Dec-07-22 04:00AM	Alvotech and STADA Broaden Access to Hukyndra® adalimumab biosimilar in Europe (GlobeNewswire) +8.72%
Dec-02-22 10:41AM	Nasdaq Iceland Approves the Request for Trading of Alvotechs Shares on the Main Market (GlobeNewswire)
Dec-01-22 05:00PM	Alvotech Announces Changes to its Leadership Team (GlobeNewswire)
Nov-30-22 02:47PM	Alvotech Submits its Application for Admission of the Companys Shares to Trading on Nasdaq Iceland Main Market (GlobeNewswire)
Nov-16-22 07:27AM	Alvotech Secures Financing Facilities of Approximately $136 Million (GlobeNewswire)
12:00AM	Alvotech Reports Financial Results for First Nine Months of 2022 And Provides Business Update (GlobeNewswire)
Nov-14-22 02:00AM	Alvotech Announces Australian Marketing Authorization for AVT02, a Biosimilar to Humira® (GlobeNewswire) +6.46%
Nov-10-22 04:00AM	Alvotech to Present Switching Study Data for AVT02, a Proposed Biosimilar to Humira®, at 2022 American College of Rheumatology Conference (GlobeNewswire) +5.47%
Oct-27-22 05:00PM	Alvotech to Report First Nine Months Financial Results on November 15, 2022 and Host Business Update Conference Call at 8:00 am ET on November 16, 2022 (GlobeNewswire)
Oct-26-22 05:00PM	Alvotech to Participate in Upcoming Jefferies London Healthcare Conference in November (GlobeNewswire)
Oct-19-22 08:38PM	Alvotech and JAMP Pharma Expand Exclusive Partnership Adding Two Biosimilar Candidates for Canadian Market, Bringing New Options for Patients in Specialty Care (PR Newswire)
Oct-17-22 05:00AM	Alvotechs Partner Submits Application for Marketing Approval of First Biosimilar Candidate in Japan (GlobeNewswire)
Oct-11-22 05:00PM	Alvotech Appoints Sarah Tanksley as Chief Quality Officer (GlobeNewswire)
Sep-22-22 08:00AM	Alvotech and STADA Increase Access to Adalimumab for Patients in Switzerland with the Launch of Hukyndra® (GlobeNewswire) -14.88%
Sep-05-22 05:00AM	Alvotech Reports Update on Initial AVT02 Biologics License Application (GlobeNewswire)
Aug-31-22 05:00PM	Alvotech Reports First Half 2022 Financial Results and Business Update (GlobeNewswire)
Aug-29-22 04:00AM	Alvotech Announces Corporate Sustainability Participation and Discloses ESG Data covering 2020 and 2021 (GlobeNewswire)
Aug-25-22 04:00AM	Alvotech Initiates Confirmatory Patient Study for AVT03, a Proposed Biosimilar for Prolia® and Xgeva® (GlobeNewswire)
Aug-24-22 04:00AM	Alvotech to Participate in Two Upcoming Investor Conferences in September 2022 (GlobeNewswire)
Aug-15-22 04:00AM	Alvotech to Report First Six Months and Second Quarter 2022 Financial Results on August 31, 2022 and Host Business Update Conference Call at 8:00 am ET on September 1, 2022 (GlobeNewswire) +18.55%
Aug-12-22 04:00AM	Alvotechs Board of Directors Approves Plan to Prepare for Listing on Nasdaq Main Market in Iceland (GlobeNewswire)
Aug-08-22 12:17PM	Alvotech (NASDAQ:ALVO): When Will It Breakeven? (Simply Wall St.)
Jul-20-22 08:00AM	Alvotech Initiates a Pharmacokinetic Study for AVT03, a Proposed Biosimilar for Prolia® and Xgeva® (GlobeNewswire) +5.87%
Jul-14-22 08:00AM	Alvotech Expands its Board of Directors as part of Transition from Private to Publicly Traded Company (GlobeNewswire)

Alvotech is a biotechnology company, which engages in the development and manufacture of biosimilar medicines. The firm is focusing on the development of its product candidates. It operates through the following geographical segments: Europe, North America, Asia, and Other. The company was founded by Robert Vilhelm Wessman in 2013 and is headquartered in Luxembourg.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ALVO

Alvotech

Upgrade your FINVIZ experience